Viewing Study NCT06000033


Ignite Creation Date: 2025-12-25 @ 2:47 AM
Ignite Modification Date: 2026-05-22 @ 2:00 AM
Study NCT ID: NCT06000033
Status: NOT_YET_RECRUITING
Last Update Posted: 2023-08-21
First Post: 2023-08-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer
Sponsor: Qilu Hospital of Shandong University
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HER2 low expression View
None Breast Cancer View
None RC48 View
None Disitamab Vedotin View